rs1554297727
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000426.4(LAMA2):c.6268+2T>C variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000426.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Publications
- congenital merosin-deficient muscular dystrophy 1AInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Myriad Women’s Health, G2P
- LAMA2-related muscular dystrophyInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- muscular dystrophy, limb-girdle, autosomal recessive 23Inheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| LAMA2 | ENST00000421865.3 | c.6268+2T>C | splice_donor_variant, intron_variant | Intron 43 of 64 | 5 | NM_000426.4 | ENSP00000400365.2 | |||
| ENSG00000226149 | ENST00000665046.1 | n.1228A>G | non_coding_transcript_exon_variant | Exon 10 of 10 | ||||||
| LAMA2 | ENST00000618192.5 | c.6532+2T>C | splice_donor_variant, intron_variant | Intron 44 of 65 | 5 | ENSP00000480802.2 | ||||
| LAMA2 | ENST00000617695.5 | c.6268+2T>C | splice_donor_variant, intron_variant | Intron 43 of 63 | 5 | ENSP00000481744.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Inborn genetic diseases Pathogenic:1
The c.6268+2T>C intronic alteration consists of a T to C substitution two nucleotides after exon 43 of the LAMA2 gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration was detected in the compound heterozygous state, with another alteration in LAMA2, in an individual with LAMA2-related muscular dystrophy (Xiong, 2015). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, this alteration is classified as likely pathogenic. -
LAMA2-related muscular dystrophy Pathogenic:1
This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 43 of the LAMA2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in LAMA2 are known to be pathogenic (PMID: 18700894, 32904964). Disruption of this splice site has been observed in individuals with congenital muscular dystrophy (PMID: 24611677; Invitae). ClinVar contains an entry for this variant (Variation ID: 477498). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at